News >

FDA Panel Backs Pexidartinib for Tenosynovial Giant Cell Tumor

Gina Columbus @ginacolumbusonc
Published: Tuesday, May 14, 2019

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 12 to 3 in favor of pexidartinib for an indication as a treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x